Page last updated: 2024-11-13

mm 36

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

difamilast: selective phosphodiesterase type‐4 (PDE4) inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57855696
CHEMBL ID3989968
SCHEMBL ID4275421
MeSH IDM0305278

Synonyms (32)

Synonym
n-[2-(4-difluoromethoxy-3-isopropoxyphenyl)oxazol-4-ylmethyl]-2-ethoxybenzamide
SCHEMBL4275421
n-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3-oxazol-4-yl}methyl)-2-ethoxybenzamide
difamilast
937782-05-3
benzamide, n-((2-(4-(difluoromethoxy)-3-(1-methylethoxy)phenyl)-4-oxazolyl)methyl)-2-ethoxy-
difamilast [jan]
opa-15406
difamilast [usan]
difamilast [who-dd]
difamilast [inn]
T3U32GLJ0F ,
n-((2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazol-4-yl)methyl)-2-ethoxybenzamide
example 352 [wo2007058338]
gtpl9776
n-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide
moizerto
usre46792, 352
bdbm389126
n-((2-(4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl)-1,3-oxazol-4-yl)methyl)-2-ethoxybenzamide
unii-t3u32glj0f
mm36
DB14987
CHEMBL3989968
D11314
difamilast (jan/usan)
MS-28058
benzamide, n-[[2-[4-(difluoromethoxy)-3-(1-methylethoxy)phenyl]-4-oxazolyl]methyl]-2-ethoxy-
HY-109085
GLXC-26792
AKOS040748251
EX-A7792

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No deaths or serious treatment-emergent adverse events were reported; all treatment-emergent adverse events were mild or moderate in severity."( Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic derm
Abe, Y; Baba, N; Oshiden, K; Saeki, H; Tsubouchi, H, 2020
)
0.56
" No difference in treatment-related adverse events was identified."( Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.
Chang, SP; Chao, CM; Lai, CC; Lan, SH; Lu, LC, 2022
)
0.72
"This meta-analysis suggests that topical difamilast is an effective and safe treatment for mild-to-moderate AD."( Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.
Chang, SP; Chao, CM; Lai, CC; Lan, SH; Lu, LC, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's7 (100.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (42.86%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (28.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]